Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1/2 1

Status

Completed 26Unknown 9Terminated 5Active not recruiting 5Recruiting 3Withdrawn 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 3Gynecologic 1

Conditions

Hodgkin Disease 3Vulvar Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1

Interventions

pembrolizumab 195Nivolumab 146Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 52Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 42Prednisone 42venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Bleomycin × Clear all
NCT03755804 2026-04-23

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
232 enrolled
Lymphoid

Hodgkin Disease, Neoplasms

NCT03407144 2026-02-19

MK-3475-667

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
340 enrolled
Lymphoid

Hodgkin Disease

NCT06715592 2025-08-08

ECT STUDY High-grade or Initially Invasive Vulva - GinOnc-ECT Study

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Phase 2 Active not recruiting
18 enrolled
Gynecologic

Vulvar Neoplasms

NCT01873326 2025-07-03

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
92 enrolled

Neoplasms, Germ Cell and Embryonal

NCT03712202 2024-11-06

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

City of Hope Medical Center

Phase 2 Active not recruiting
155 enrolled
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡